X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9) 9
aged (8) 8
humans (8) 8
female (7) 7
male (7) 7
middle aged (7) 7
chemotherapy (6) 6
adult (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
lung neoplasms - drug therapy (4) 4
oncology (4) 4
analysis (3) 3
disease-free survival (3) 3
gefitinib (3) 3
health aspects (3) 3
lung cancer (3) 3
lung cancer, non-small cell (3) 3
mutation (3) 3
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
biopsy (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
clinical trials (2) 2
disease (2) 2
erbb receptors - genetics (2) 2
erlotinib (2) 2
growth-factor receptor (2) 2
health care industry (2) 2
health care sciences & services (2) 2
internal medicine (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - pathology (2) 2
medicine & public health (2) 2
metastases (2) 2
nsclc (2) 2
nurses (2) 2
patients (2) 2
physicians (2) 2
survival (2) 2
t790m mutation (2) 2
therapy (2) 2
treatment outcome (2) 2
tumors (2) 2
tyrosine (2) 2
young adult (2) 2
1st-line therapy (1) 1
abridged index medicus (1) 1
acquired-resistance (1) 1
adenocarcinoma (1) 1
adolescent (1) 1
afatinib (1) 1
age (1) 1
aged, 80 and over (1) 1
agent (1) 1
anti-pd-l1 antibody (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antiemetics (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents, alkylating - administration & dosage (1) 1
antineoplastic agents, alkylating - adverse effects (1) 1
antineoplastic agents, alkylating - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
anxiety (1) 1
apoptosis (1) 1
apoptosis - drug effects (1) 1
apoptosis - genetics (1) 1
apoptosis regulatory proteins - genetics (1) 1
apoptosis regulatory proteins - metabolism (1) 1
aprepitant (1) 1
article (1) 1
b7-h1 antigen - analysis (1) 1
bcl-2-like protein 11 (1) 1
behavior modification (1) 1
behavior therapy - economics (1) 1
behavior therapy - methods (1) 1
bevacizumab - administration & dosage (1) 1
bim protein (1) 1
biomarkers (1) 1
blockade (1) 1
brca1 (1) 1
breast (1) 1
breast-cancer (1) 1
cancer patients (1) 1
cancer therapies (1) 1
cancer-chemotherapy (1) 1
carcinoma, non-small-cell lung - chemistry (1) 1
care and treatment (1) 1
care management (1) 1
cell activation (1) 1
cell phone (1) 1
cell proliferation (1) 1
cell survival (1) 1
chemotherapy induced emesis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers
Journal Article
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 5, pp. 435 - 444
Journal Article
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, p. 17499
BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may... 
APOPTOSIS | THERAPY | MESSENGER-RNA EXPRESSION | EURTAC | MULTIDISCIPLINARY SCIENCES | KINASE | MUTATIONS | BRCA1 | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Middle Aged | Apoptosis - genetics | Lung Neoplasms - pathology | Male | RNA, Messenger - metabolism | TOR Serine-Threonine Kinases - genetics | Bcl-2-Like Protein 11 | Apoptosis Regulatory Proteins - genetics | Inhibitory Concentration 50 | Female | Membrane Proteins - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Membrane Proteins - genetics | RNA, Messenger - genetics | Proto-Oncogene Proteins - genetics | Treatment Outcome | Signal Transduction - genetics | Mutation - genetics | Apoptosis Regulatory Proteins - metabolism | Disease-Free Survival | Signal Transduction - drug effects | Quinazolines - therapeutic use | Erlotinib Hydrochloride - pharmacology | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Cohort Studies | Tyrosine | TOR protein | Cell proliferation | Adenocarcinoma | Epidermal growth factor receptors | Lung cancer | Non-small cell lung carcinoma | Tumor cell lines | Gene expression | Kinases | Cell activation | Gefitinib | Protein-tyrosine kinase | BIM protein | Apoptosis | Phosphodiesterase
Journal Article
Journal Article
by Ramallo-Fariña, Yolanda and García-Pérez, Lidia and Castilla-Rodríguez, Iván and Perestelo-Pérez, Lilisbeth and Wägner, Ana María and de Pablos-Velasco, Pedro and Domínguez, Armando Carrillo and Cortés, Mauro Boronat and Vallejo-Torres, Laura and Ramírez, Marcos Estupiñán and Martín, Pablo Pedrianes and García-Puente, Ignacio and Salinero-Fort, Miguel Ángel and Serrano-Aguilar, Pedro Guillermo and de la Rosa, Abraham Pérez and Figueroa, Águeda Caballero and Pérez, Alejandro Guerra and Ríos, Alicia Pareja and carrillo, Alicia Pérez and Perello, Andrés Sifre and Pérez, Ángela Trinidad Gutiérrez and Cejas, Antonia Pilar Pérez and de León, Antonio Cabrera and Quintana, Antonio García and Domínguez, Bernardo Eusebio Herrera and Pérez, Carlos Sedeño and Alberto, Carlos Martínez and álamo, Carlos Ramírez and Aguilar, Carmen Daranas and Marrero, Carolina Guerra and Soto, Cecilia Lobos and Pérez, Cristina Padrón and Vega, Cristina Sánchez and Marte, Dácil Alvarado and Obregón, Daniel Hernández and de la Cruz Paz, Dionisio and Correa, Dulce N Hernández and Pozuelo, Elsa Espinosa and Mayor, Elsa Florido and Domínguez, Engracia Pinilla and García, Fátima Herrera and Aguiar, Félix Bonilla and álvarez, Fernando Montón and López, Francisco Cabrera and Jerónimo, Jose Francisco Ferraz and Díaz, Francisco Hernández and de la Torre, Gloria Guerra and Martín, Gregorio Muelas and Monzón, Guillermo Monzón and Arregui, Guillermo Rizo and de la Rosa Merino, Héctor and de Segura, Ignacio Llorente Gómez and Calcerrada, Isabel García and Pérez, Jacqueline álvarez and Page, Jorge Federico Aldunate and Dopico, Jose Antonio García and Sánchez, José Juan Alemán and Hernández, José Miguel Salamanca and Santana, Jose Ramón Medina and Hernández, Juan Andrés Báez and Valencia, Juan José Pérez and Samper, Juan Luis Burgazzoli and Wiebe, Julia Charlotte and Martín, Leopoldo Martín and Rodríguez, Leticia Rodríguez and Majem, Lluis Serra and Herrera, Luis Morcillo and Ruano, Margarita Roldán and del Mar Romero Fernández, María and Pérez, María Inmaculada González and Morales, María Isabel Visuerte and Medina, María Pino Afonso and Ruiz, Marta Riaño and Santana, Marta Tejera and Medina, Mercedes Lorenzo and García, Miguel Juan Mora and Picos, Miguel Pico and Sánchez-Somoza, Mónica Belinchón and Delgado, Nayra Pérez and Arias, Oliver Rivero and Alba, Pilar Peláez and López, Rafael Valcárcel and Sánchez, Remedios Castro and Ajamil, Rita Tristancho and Fernández, Roberto Martín and González, Rodrigo Abreu and Trujillo, Rosa Borges and Díaz, Rosa María Suárez and González, Salvador Acosta and Girardot, Sybille Kaiser and Sellarés, Víctor Lorenzo and INDICA Team and INDICA team
Implementation Science, ISSN 1748-5908, 04/2015, Volume 10, Issue 1, p. 47
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.